Please assess the completion status of the following clinical trial:

Trial Title: Ferric Carboxymaltose to Improve Skeletal Muscle Metabolism in Heart Failure Patients With Functional Iron Deficiency

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Symptomatic NYHA Class II-III heart failure \>3 months~* Guideline-recommended heart failure treatment for \> 3 months~* Hemoglobin \>13 g/dl for men and \>12 g/dl for women~* Functional iron deficiency (defined as serum ferritin level \<100 ng/ml or between 100 and 299 ng/ml with transferrin saturation \<20%)~* Left ventricular ejection fraction \<40%, or left ventricular ejection fraction ≥40% with left atrial enlargement (left atrial volume index \>28 ml/m2) and/or left ventricular hypertrophy (left ventricular mass index \>95 g/m2 (women) or \>115 g/m2 (men) determined by echocardiogram within last 24 months.~* Able and willing to provide written informed consent~Exclusion Criteria:~* Presence of implantable defibrillator, permanent pacemaker, other metal implant not compatible with 3TMRS/MRI, or other contraindication to 3T MRS/MRI procedures~* Heart failure due to infiltrative cardiomyopathy, restrictive cardiomyopathy, or hypertrophic cardiomyopathy~* Weight \<50 kg or \>120 kg~* Coronary or cerebral atherothrombotic events in the past 6 months~* Hospitalization of emergency room visit for heart failure within past 3 months~* ICD shock in last 3 months~* Known peripheral artery disease or ankle-brachial index \<0.9 at screening visit~* Exercise primarily limited by angina, lung disease or neuromuscular disease~* Systolic blood pressure \<100 or \>160 mmHg~* Heart rate \<50 or \>110 min-1~* Estimated glomerular filtration rate \<30 ml/min~* Liver function tests \>3 times upper limit of normal~* Serum phosphate below normal limit~* Pregnant or breast-feeding women~* Women of child-bearing potential unwilling to use recommended contraception methods during the study~* Treatment with oral iron supplements (except multivitamins) in past year~* Treatment with intravenous iron in past year~* Treatment with erythropoiesis stimulating agents in the past year~* Known intolerance of intravenous iron~* History of anaphylaxis~* Participation in another clinical trial within last 30 days.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Ferric Carboxymaltose (Type: EXPERIMENTAL): HF patients with functional iron deficiency assigned to receive one-time dose of Ferric Carboxymaltose 750 mg. Participants will undergo serial assessment before and 4 weeks after study drug administration
- Placebo (Type: ACTIVE_COMPARATOR): HF patients with functional iron deficiency assigned to receive one-time dose of Placebo (saline injection). Participants will undergo serial assessment before and 4 weeks after study drug administration.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues